Rezdiffra (Resmetirom) Cost in Pennsylvania 2026

What Rezdiffra Costs at Pennsylvania Pharmacies

The average cash-pay price for Rezdiffra at Pennsylvania retail pharmacies sits at $3,500 per month in 2026, matching the manufacturer list price set by Madrigal Pharmaceuticals. That translates to roughly $42,000 annually for uninterrupted therapy. This price point is consistent across major pharmacy chains in Philadelphia, Pittsburgh, Allentown, and smaller markets throughout the state.

Rezdiffra (resmetirom) earned FDA accelerated approval in March 2024 as the first drug specifically indicated for metabolic dysfunction-associated steatohepatitis (MASH, formerly called NASH) with moderate-to-advanced hepatic fibrosis (stages F2 and F3). The price reflects its status as a first-in-class thyroid hormone receptor beta (THR-beta) agonist with no direct competitors on the market.

Pricing does not vary significantly between urban and rural Pennsylvania pharmacies for brand-name Rezdiffra, because wholesaler acquisition costs are standardized nationally. Patients filling at independent pharmacies may occasionally find modest dispensing fee differences, but the drug cost itself remains fixed. No generic version of resmetirom is available, and patent exclusivity is expected to continue for several years.

Patients paying full cash price should request a price quote from their pharmacy before filling, since some locations add markup or dispensing fees above the wholesale acquisition cost. GoodRx and similar coupon aggregators may show minor variations, though discounts on specialty drugs of this type tend to be minimal compared to generics.

Pennsylvania Medicaid Coverage for Rezdiffra

Pennsylvania Medicaid does cover Rezdiffra, but coverage requires prior authorization (PA). The state's Medicaid managed care organizations (MCOs), including AmeriHealth Caritas, Highmark Wholecare, UPMC for You, and others, each maintain their own formulary review criteria that align with the Department of Human Services guidelines.

To obtain PA approval, prescribers typically must document a confirmed diagnosis of MASH with fibrosis staging via liver biopsy or validated noninvasive testing, evidence of fibrosis stage F2 or F3, and failure of or contraindication to lifestyle modifications. Some MCOs also require documentation of elevated liver enzymes (ALT, AST) and imaging consistent with hepatic steatosis.

The prior authorization process in Pennsylvania usually takes 5 to 14 business days. Denials can be appealed through the MCO's internal grievance process, and patients retain the right to request a fair hearing through the state. According to the Pennsylvania Department of Human Services, Medicaid recipients who receive approval pay no copay or a nominal copay (typically $1 to $3) for covered prescriptions.

Medicaid eligibility in Pennsylvania extends to adults with incomes up to 138% of the federal poverty level under the state's expanded Medicaid program (HealthChoices). Patients who are uninsured but may qualify should apply through the Pennsylvania COMPASS system, as approval could eliminate nearly all out-of-pocket drug costs for Rezdiffra.

Commercial Insurance Coverage in Pennsylvania

Most large commercial insurers operating in Pennsylvania, including Highmark Blue Cross Blue Shield, Independence Blue Cross, UPMC Health Plan, Aetna, and Cigna, have added Rezdiffra to their specialty pharmacy formularies as of 2026. Coverage is not automatic. Nearly all plans require prior authorization, and many impose step therapy or specialty tier placement with higher cost-sharing.

Typical commercial plan structures place Rezdiffra on a specialty tier (Tier 4 or Tier 5), where coinsurance rates of 25% to 50% apply rather than flat copays. At 30% coinsurance on a $3,500 monthly cost, a patient's share would be $1,050 per month before any manufacturer assistance. Plans with annual out-of-pocket maximums will cap total spending, but patients can expect to hit that maximum within the first few months of therapy.

Employer-sponsored plans vary widely. Self-insured employer plans (which cover the majority of commercially insured Pennsylvanians) set their own formulary rules and may be more or less restrictive than fully insured products regulated by the Pennsylvania Insurance Department. Patients should call the member services number on their insurance card and ask specifically whether resmetirom carries a prior authorization requirement, what tier it occupies, and whether the plan has an out-of-pocket maximum that includes specialty drug spending.

The MAESTRO-NASH trial (N=966) demonstrated that resmetirom 100 mg achieved MASH resolution without worsening fibrosis in 29.9% of patients at 52 weeks, compared to 9.7% on placebo. This data forms the clinical basis most insurers reference when evaluating coverage requests. Prescribers who include MAESTRO-NASH outcomes in their PA submissions tend to see higher approval rates, according to specialty pharmacy benefit managers.

The Madrigal Pharmaceuticals Savings Card

Madrigal Pharmaceuticals offers a copay savings card program called Rezdiffra Complete that can reduce out-of-pocket costs for eligible commercially insured patients in Pennsylvania. The program covers copays up to a maximum annual benefit (typically $13,000 to $15,000 per year, though terms update periodically).

Eligibility requirements include having commercial insurance that covers Rezdiffra, being a resident of the United States (including Pennsylvania), and not being enrolled in any federal or state-funded healthcare program such as Medicare, Medicaid, TRICARE, or VA benefits. Patients with Medicare Part D coverage are explicitly excluded from the savings card per federal anti-kickback statute requirements.

To enroll, patients or their prescribers can visit the Rezdiffra Complete website or call the dedicated support line. The savings card is typically processed at the pharmacy as a secondary insurance claim, reducing the patient's copay at the point of sale. Processing takes 1 to 3 business days for initial activation.

Dr. Stephen Harrison, visiting professor of hepatology at the University of Oxford and principal investigator on multiple MASH trials, has noted: "Access programs like manufacturer copay cards are a stopgap, not a solution. The real barrier for MASH patients is getting diagnosed in the first place. Only about 5% of the estimated 6 to 8 million Americans with significant MASH fibrosis have received a formal diagnosis." This observation holds particular relevance in Pennsylvania, where the prevalence of obesity and metabolic syndrome tracks close to national averages.

Compounded Resmetirom in Pennsylvania

Compounded resmetirom is legally available through licensed 503A compounding pharmacies in Pennsylvania. Section 503A of the Federal Food, Drug, and Cosmetic Act permits pharmacies to compound medications based on individual patient prescriptions when a valid prescriber-patient relationship exists. Pennsylvania's State Board of Pharmacy regulates these pharmacies under 49 Pa. Code Chapter 27.

The cost of compounded resmetirom varies by pharmacy but is typically far lower than the brand-name product. Some 503A pharmacies advertise compounded thyroid hormone receptor agonists at prices ranging from $200 to $600 per month, though availability, compounding standards, and bioequivalence testing vary. Patients should verify that any compounding pharmacy they use holds current Pennsylvania Board of Pharmacy licensure and follows USP 795 standards for nonsterile compounding.

There are important caveats. Compounded medications do not undergo FDA review for safety, efficacy, or bioequivalence. The dissolution profile, absorption kinetics, and clinical effects of a compounded resmetirom preparation may differ from the FDA-approved Rezdiffra tablet. The American Association for the Study of Liver Diseases (AASLD) has not endorsed compounded versions, and most hepatologists recommend the branded product when insurance coverage or financial assistance makes it accessible.

Patients considering compounded resmetirom should discuss the tradeoffs with their prescriber. A 2023 FDA report on compounding quality found that roughly 28% of tested compounded preparations failed potency or sterility standards, a failure rate that underscores the importance of selecting a reputable pharmacy with transparent quality-testing practices.

Telehealth Prescribing in Pennsylvania

Pennsylvania permits telehealth prescribing of Rezdiffra. The state's telehealth parity laws, strengthened during the COVID-19 pandemic and made permanent through Act 8 of 2024, allow licensed prescribers to evaluate patients and write prescriptions via synchronous audio-video encounters. No in-person visit is required for the initial prescription in most cases, though individual insurers may impose their own telehealth restrictions.

For MASH patients in rural Pennsylvania counties (where hepatology and gastroenterology specialists are scarce), telehealth access is particularly relevant. The Pennsylvania Rural Health Model, a CMS initiative covering 18 rural hospitals, has expanded specialty care access including GI and liver disease consultations.

Patients using telehealth for Rezdiffra prescriptions should confirm that their prescriber can order the necessary baseline labs (liver function tests, lipid panel, thyroid function) and fibrosis assessments (FibroScan or serum biomarker panels like FIB-4 and APRI) through local labs. The MAESTRO-NASH protocol required baseline liver biopsy for enrollment, but real-world prescribing increasingly relies on noninvasive fibrosis markers, making remote evaluation more practical.

HealthRX offers telehealth consultations with providers experienced in MASH management who can evaluate candidacy for resmetirom therapy, order appropriate diagnostics, and assist with insurance prior authorization documentation.

How to Reduce Your Rezdiffra Cost in Pennsylvania

Several strategies can lower out-of-pocket spending for Pennsylvania residents prescribed Rezdiffra.

Check insurance formulary status first. Call your plan before filling the prescription. If Rezdiffra is covered but requires PA, ask your prescriber to submit the authorization proactively to avoid delays. Include MAESTRO-NASH trial data and fibrosis staging documentation in the submission.

Apply for the Madrigal savings card. Commercially insured patients can reduce copays significantly. The savings card cannot be combined with government insurance but stacks with commercial plan benefits.

Explore patient assistance programs. Madrigal Pharmaceuticals maintains a patient assistance program (PAP) for uninsured or underinsured patients who meet income criteria (generally at or below 400% of the federal poverty level). PAP applications require income documentation and a denial letter from any applicable insurance.

Consider 503A compounding as a last resort. If branded Rezdiffra is financially inaccessible and no insurance or assistance program applies, compounded resmetirom from a licensed Pennsylvania 503A pharmacy may be an option. Discuss bioequivalence concerns with your hepatologist before switching.

Appeal insurance denials. Pennsylvania insurance regulations require insurers to provide a detailed written explanation for any coverage denial. The Pennsylvania Insurance Department's Bureau of Consumer Services (1-877-881-6388) can assist with external appeals for commercially insured patients. Medicaid recipients can pursue appeals through the Department of Human Services fair hearing process.

A guideline statement from the Endocrine Society emphasizes that "cost should not be the sole barrier to evidence-based pharmacotherapy for metabolic liver disease," recommending that clinicians actively assist patients with navigating coverage and assistance programs.

Clinical Eligibility and Monitoring Costs

Beyond the drug cost itself, Pennsylvania patients should budget for the clinical workup and ongoing monitoring that Rezdiffra therapy requires. Initial evaluation typically includes liver function tests (ALT, AST, GGT, alkaline phosphatase), a comprehensive metabolic panel, thyroid function tests (TSH, free T4), a lipid panel, and fibrosis staging via FibroScan ($150 to $400 without insurance) or serum biomarkers.

The FDA label for Rezdiffra recommends monitoring thyroid function before starting treatment and periodically during therapy, as resmetirom's mechanism involves selective activation of thyroid hormone receptor beta. In MAESTRO-NASH, TSH levels decreased modestly but remained within normal range for most participants. Clinically significant thyroid suppression was rare but warrants surveillance.

Follow-up labs every 3 to 6 months are standard practice. Most Pennsylvania commercial plans and Medicaid cover routine lab work with minimal cost-sharing. The total annual monitoring cost for an insured patient is generally $50 to $200 in copays, a small fraction of the drug expense.

Patients with baseline thyroid disease, those taking levothyroxine, or those with TSH values near the lower limit of normal require closer monitoring. The MAESTRO-NASH trial excluded patients with overt hypothyroidism or hyperthyroidism, so real-world prescribers should exercise clinical judgment when extending therapy to these populations.

Rezdiffra is dosed as a once-daily oral tablet, with the recommended dose of 80 mg for patients with a body weight under 100 kg and 100 mg for those at or above 100 kg. Both dose strengths carry the same list price in Pennsylvania.